Название продукции:(R)-2-tert-Butyl 8a-methyl 6-oxo-3,4,6,7,8,8a-hexahydroisoquinoline-2,8a(1H)-dicarboxylate

IUPAC Name:2-tert-butyl 8a-methyl (8aR)-6-oxo-1,2,3,4,6,7,8,8a-octahydroisoquinoline-2,8a-dicarboxylate

CAS:445312-74-3
Молекулярная формула:C16H23NO5
Чистота:97%
Номер в каталоге:CM229457
Молекулярная масса:309.36

Упаковочная единица Доступно для заказа Цена ($) Количество
CM229457-10g in stock džŸƴǠ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:445312-74-3
Молекулярная формула:C16H23NO5
Точка плавления:-
Smiles-код:O=C(N(CCC1=C2)C[C@@]1(C(OC)=O)CCC2=O)OC(C)(C)C
Плотность:
Номер в каталоге:CM229457
Молекулярная масса:309.36
Точка кипения:
Номер Mdl:
Хранение:

Column Infos

Relacorilant
Corcept completes enrollment in phase 3 Gradient trial of Relacorilant in patients with Adrenal Cushing’s Syndrome. Cushing's disease or hypercortisolism is a rare endocrine disorder that occurs when a pituitary adenoma makes excessive cortisol. Cortisol exerts its functions by binding to the glucocorticoid receptor (GR).
Relacorilant is a selective glucocorticoid receptor modulator (SGRM) in clinical development to prevent the effects of high cortisol. Relacorilant is being studied in various serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome.